Osteoporosis is a progressive, systemic skeletal disease characterized by decreased bone mass and micro-architectural deterioration of bone tissue leading to increased bone fragility and susceptibility to fractures.
The more risk factors (eg history of fracture, advanced age, comorbidities, etc) that are present, the greater the risk of fracture.
Very low thoracic bone mineral density (BMD) measured on cardiac CT scan is predictive of a higher fracture risk, especially osteoporosis-related fracture — thus highlighting the potential utility of cardiac CT for opportunistic BMD screening.
Patients with chronic obstructive pulmonary disease (COPD) who initiate treatment with inhaled corticosteroids (ICS) may have an elevated risk of developing type 2 diabetes mellitus (T2DM), according to a matched cohort study.
High exposure to triclosan, an antibacterial agent commonly found in consumer products, is associated with low bone mineral density (BMD) and an increased risk of osteoporosis among women, suggests epidemiological data from the NHANES*.
Postmenopausal women who are younger, have higher levels of the bone turnover marker sCTX, and did not receive zoledronate prior to initiating denosumab treatment have an elevated risk of significant bone mineral density (BMD) loss 1 year after denosumab discontinuation, according to results of the ReoLaus* Bone Project presented at EULAR 2019.
Administration of the RANKL* inhibitor denosumab prior to chemotherapy initiation may prevent secondary reduction in bone mineral density (BMD) induced by chemotherapy, according to the ESPRESSO-02 study presented at ESMO Asia 2018.
Zoledronate significantly reduces the risk of both nonvertebral and vertebral fragility fractures over 6 years in older women with osteopenia — a substantial patient group at risk for fractures but in whom a knowledge gap remains for pharmacological treatment, reveals a large randomized trial.
At the Novartis-sponsored VERIFY Soft Launch held at Le Meridien, Kuala Lumpur, two distinguished speakers spoke on the latest updates in glucose-lowering therapy and the benefit of early treatment intensification using combination therapy (ie, vildagliptin/metformin) in the management of T2DM.